Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.
BERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...
BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...
BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...
BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today...
On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal...
BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.070885 | 26.2537037037 | 0.27 | 0.3681 | 0.23 | 2075465 | 0.26369049 | CS |
| 4 | 0.001885 | 0.55604719764 | 0.339 | 0.3681 | 0.1852 | 2204756 | 0.25950568 | CS |
| 12 | -0.075715 | -18.1745079213 | 0.4166 | 0.4751 | 0.1852 | 1725770 | 0.3209668 | CS |
| 26 | -0.749115 | -68.726146789 | 1.09 | 1.13 | 0.1852 | 1097081 | 0.37891667 | CS |
| 52 | -2.529115 | -88.1224738676 | 2.87 | 3.3923 | 0.1852 | 631210 | 0.49145013 | CS |
| 156 | -14.009115 | -97.6244947735 | 14.35 | 30 | 0.1852 | 302844 | 3.96759593 | CS |
| 260 | -14.009115 | -97.6244947735 | 14.35 | 30 | 0.1852 | 302844 | 3.96759593 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
